NEW YORK (GenomeWeb News) – Teva Pharmaceuticals will be the exclusive distributor of MDxHealth's tests for prostate cancer and glioblastoma in Israel under a deal announced today.
The three-year agreement provides Teva the exclusive rights to distribute MDxHealth's ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma in Israel. MDxHealth will analyze samples in its CLIA-registered laboratory in Irvine, Calif., and Teva will reimburse MDxHealth for all testing services.
MDxHealth CEO Jan Groen said in a statement that Israel is the firm's second market after the US. Further details of the deal were not disclosed.
ConfirmMDx provides actionable information to physicians that they can use to improve patient care, MDxHealth said, noting it can help reduce the frequency of unnecessary repeat prostate biopsies. PredictMDx is for identifying glioma patients with methylation of the MGMT gene.